These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 31167516)

  • 21. Serum immunoglobulin G antibodies to Porphyromonas gingivalis, Prevotella intermedia, Fusobacterium nucleatum and Streptococcus sanguis during experimental gingivitis in young adults.
    Danielsen B; Wilton JM; Baelum V; Johnson NW; Fejerskov O
    Oral Microbiol Immunol; 1993 Jun; 8(3):154-60. PubMed ID: 8233568
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Induction of systemic murine B-cell responses by Fusobacterium nucleatum and Porphyromonas gingivalis.
    Nunes IP; Jonsson R; Jensen HB; Bakken V
    Oral Microbiol Immunol; 1996 Jun; 11(3):142-9. PubMed ID: 8941767
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Periodontal disease, Porphyromonas gingivalis serum antibody levels and orodigestive cancer mortality.
    Ahn J; Segers S; Hayes RB
    Carcinogenesis; 2012 May; 33(5):1055-8. PubMed ID: 22367402
    [TBL] [Abstract][Full Text] [Related]  

  • 24.
    Liu S; Zhou X; Peng X; Li M; Ren B; Cheng G; Cheng L
    J Immunol; 2020 Jul; 205(1):282-289. PubMed ID: 32471882
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum antibodies to Porphyromonas gingivalis chaperone HtpG predict health in periodontitis susceptible patients.
    Shelburne CE; Shelburne PS; Dhople VM; Sweier DG; Giannobile WV; Kinney JS; Coulter WA; Mullally BH; Lopatin DE
    PLoS One; 2008 Apr; 3(4):e1984. PubMed ID: 18431474
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunological Pathways Triggered by
    de Andrade KQ; Almeida-da-Silva CLC; Coutinho-Silva R
    Mediators Inflamm; 2019; 2019():7241312. PubMed ID: 31341421
    [No Abstract]   [Full Text] [Related]  

  • 27. Porphyromonas gingivalis initiates a mesenchymal-like transition through ZEB1 in gingival epithelial cells.
    Sztukowska MN; Ojo A; Ahmed S; Carenbauer AL; Wang Q; Shumway B; Jenkinson HF; Wang H; Darling DS; Lamont RJ
    Cell Microbiol; 2016 Jun; 18(6):844-58. PubMed ID: 26639759
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Salivary pathogen and serum antibody to assess the progression of chronic periodontitis: a 24-mo prospective multicenter cohort study.
    Morozumi T; Nakagawa T; Nomura Y; Sugaya T; Kawanami M; Suzuki F; Takahashi K; Abe Y; Sato S; Makino-Oi A; Saito A; Takano S; Minabe M; Nakayama Y; Ogata Y; Kobayashi H; Izumi Y; Sugano N; Ito K; Sekino S; Numabe Y; Fukaya C; Yoshinari N; Fukuda M; Noguchi T; Kono T; Umeda M; Fujise O; Nishimura F; Yoshimura A; Hara Y; Nakamura T; Noguchi K; Kakuta E; Hanada N; Takashiba S; Yoshie H
    J Periodontal Res; 2016 Dec; 51(6):768-778. PubMed ID: 26791469
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Porphyromonas gingivalis promotes the progression of oral squamous cell carcinoma by stimulating the release of neutrophil extracellular traps in the tumor immune microenvironment.
    Guo ZC; Jing SL; Jia XY; Elayah SA; Xie LY; Cui H; Tu JB; Na SJ
    Inflamm Res; 2024 May; 73(5):693-705. PubMed ID: 38150024
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Research progress on the relationship between Porphyromonas gingivalis and oral squamous cell carcinoma].
    Wu-chao W; Yafei W; Lei Z
    Hua Xi Kou Qiang Yi Xue Za Zhi; 2015 Dec; 33(6):651-5. PubMed ID: 27051963
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of Porphyromonas gingivalis in oral squamous cell carcinoma development: A systematic review.
    Lafuente Ibáñez de Mendoza I; Maritxalar Mendia X; García de la Fuente AM; Quindós Andrés G; Aguirre Urizar JM
    J Periodontal Res; 2020 Jan; 55(1):13-22. PubMed ID: 31529626
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Coinfection with Fusobacterium nucleatum can enhance the attachment and invasion of Porphyromonas gingivalis or Aggregatibacter actinomycetemcomitans to human gingival epithelial cells.
    Li Y; Guo H; Wang X; Lu Y; Yang C; Yang P
    Arch Oral Biol; 2015 Sep; 60(9):1387-93. PubMed ID: 26143497
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum IgG to heat shock proteins and Porphyromonas gingivalis antigens in diabetic patients with periodontitis.
    Sims TJ; Lernmark A; Mancl LA; Schifferle RE; Page RC; Persson GR
    J Clin Periodontol; 2002 Jun; 29(6):551-62. PubMed ID: 12296783
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dynamics of serum immunoglobulin G avidity for Porphyromonas gingivalis in adult periodontitis.
    Takahashi J; Saito A; Nakagawa T; Yamada S; Ishihara K; Okuda K
    J Periodontol; 1998 Mar; 69(3):367-73. PubMed ID: 9579624
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interleukin 6 and interleukin 8 as potential biomarkers for oral cavity and oropharyngeal squamous cell carcinoma.
    St John MA; Li Y; Zhou X; Denny P; Ho CM; Montemagno C; Shi W; Qi F; Wu B; Sinha U; Jordan R; Wolinsky L; Park NH; Liu H; Abemayor E; Wong DT
    Arch Otolaryngol Head Neck Surg; 2004 Aug; 130(8):929-35. PubMed ID: 15313862
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interleukin 1, interleukin 6 and transforming growth factor-beta production by human gingival mononuclear cells following stimulation with Porphyromonas gingivalis and Fusobacterium nucleatum.
    Gemmell E; Seymour GJ
    J Periodontal Res; 1993 Mar; 28(2):122-9. PubMed ID: 8386762
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Converging findings from linkage between periodontal pathogen with atopic and allergic immune response.
    Nelwan SC; Nugraha RA; Endaryanto A; Meizarini A; Tedjosasongko U; Pradopo S; Utomo H
    Cytokine; 2019 Jan; 113():89-98. PubMed ID: 29937409
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of periodontal treatments on serum IgG antibody titers against periodontopathic bacteria.
    Horibe M; Watanabe H; Ishikawa I
    J Clin Periodontol; 1995 Jul; 22(7):510-5. PubMed ID: 7560233
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Porphyromonas gingivalis suppresses oral squamous cell carcinoma progression by inhibiting MUC1 expression and remodeling the tumor microenvironment.
    Lan Z; Zou KL; Cui H; Zhao YY; Yu GT
    Mol Oncol; 2024 May; 18(5):1174-1188. PubMed ID: 37666495
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Titer and avidity of serum antibody to Porphyromonas gingivalis before and after periodontal therapy].
    Ouyang X; Cao C; Chen Z
    Zhonghua Kou Qiang Yi Xue Za Zhi; 2000 May; 35(3):188-90. PubMed ID: 11780220
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.